News

Marksans Pharma has completed the process of acquiring 100% share capital of ABCnow GmbH based in Germany.

Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with front end sales, marketing, and distribution capabilities across German healthcare market. The company will acquire entire shareholding of ABCnow GmbH for a total consideration of � 892,384. The acquisition marks a strategic step in expanding Marksans` presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans` presence in the European markets.

Marksans Pharma announced that the 34th Annual General Meeting(AGM) of the company will be held on 27 August 2026.

Marksans Pharma has completed the acquisition of 100% share capital of QliniQ B.V. based in the Netherlands.

Marksans Pharma has received affirmation in credit ratings for bank facilities at IND AA-/ IND A1+ while outlook has been revised to `Positive` from `Stable`.